Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)
Frequently Asked Questions About Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)
How can investors keep track of Salarius Pharmaceuticals' updates?
Investors can keep track of updates from Salarius Pharmaceuticals by following the company’s official website, subscribing to their investor relations communications, and monitoring press releases and SEC filings. Additionally, they can participate in earnings calls and industry conferences to gain insights into the company’s progress and outlook.
How does Salarius Pharmaceuticals ensure regulatory compliance?
Salarius Pharmaceuticals rigorously follows regulatory guidelines set forth by organizations such as the U.S. Food and Drug Administration (FDA) and other international regulatory bodies. The company ensures compliance by adhering to Good Clinical Practice (GCP), maintaining thorough documentation, and preparing for audits and inspections.
How does Salarius Pharmaceuticals raise capital?
Salarius Pharmaceuticals raises capital through various means, including public offerings of its stock, private placements, collaborations with pharmaceutical companies, and grants. The ability to raise capital is essential for funding its research, clinical trials, and operational expenses.
How does Salarius Pharmaceuticals' drug development differ from traditional methods?
Salarius Pharmaceuticals employs a unique approach by focusing on epigenetic therapy, which targets the mechanisms that regulate gene expression in cancer cells. This strategy aims to inhibit cancer cell growth and restore normal cellular functions, offering a potentially more effective treatment alternative compared to traditional methods that may only attack the tumor directly.
Is Salarius Pharmaceuticals publicly traded?
Yes, Salarius Pharmaceuticals is a publicly traded company. It became publicly listed on the Nasdaq stock exchange, providing the company with access to capital markets to fund its research and development activities and operational expenses.
What are the future plans for Salarius Pharmaceuticals?
Salarius Pharmaceuticals plans to continue advancing its pipeline of drug candidates through clinical trials, with a focus on obtaining regulatory approvals for its lead products. The company also aims to explore additional collaborations, expand research activities, and potentially broaden its therapeutic portfolio to address more cancer types.
What are the main drug candidates in Salarius Pharmaceuticals' pipeline?
Salarius Pharmaceuticals' pipeline includes several drug candidates, with its lead product, Seclidemstat, which is an epigenetic-modulating agent designed to treat certain types of solid tumors and hematological malignancies. The company is conducting clinical trials to evaluate the safety and efficacy of this drug in various patient populations.
What does Salarius Pharmaceuticals, Inc. do?
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company specializes in the development of targeted drugs designed to treat a variety of cancers, including rare and hard-to-treat tumors. Their lead product candidate is a novel approach aiming to enhance the standard of care by improving efficacy and minimizing side effects.
What is Salarius Pharmaceuticals' mission?
Salarius Pharmaceuticals' mission is to develop and deliver innovative therapeutic solutions to patients battling cancer. The company aims to enhance treatment options that provide better responses, fewer side effects, and improved quality of life, ultimately making a positive impact on oncology care.
What is Seclidemstat's mechanism of action?
Seclidemstat is designed to modulate epigenetic factors that influence gene expression in cancer cells. By targeting these epigenetic regulators, Seclidemstat aims to reverse abnormal cancer cell behavior, inhibit tumor growth, and enhance the effectiveness of existing cancer treatments.
What is the significance of Salarius Pharmaceuticals' research?
The research conducted by Salarius Pharmaceuticals is significant as it addresses unmet medical needs in cancer treatment. By developing targeted therapies that attack the underlying mechanisms of cancer, the company aims to enhance treatment outcomes, improve survival rates, and offer new hope to patients diagnosed with challenging cancer types.
What is the stock symbol for Salarius Pharmaceuticals?
Salarius Pharmaceuticals trades on the Nasdaq stock exchange under the ticker symbol 'SLRX'. This designation allows investors to easily find and trade shares of the company on one of the major U.S. exchanges.
What partnerships or collaborations does Salarius Pharmaceuticals have?
Salarius Pharmaceuticals has engaged in collaborations with academic institutions, research organizations, and industry partners to advance its drug development programs. These collaborations aim to leverage expertise, share resources, and enhance the clinical development process.
What stages are Salarius Pharmaceuticals’ clinical trials in?
Salarius Pharmaceuticals is involved in various stages of clinical trials, including Phase 1 and Phase 2 trials for its lead drug candidate, Seclidemstat. These trials are designed to assess the drug’s safety, tolerability, and preliminary efficacy in patients, depending on the stage of development.
What types of cancers is Salarius Pharmaceuticals targeting?
Salarius Pharmaceuticals is primarily focusing on treating solid tumors and hematological malignancies. This includes cancers such as sarcoma and other rare tumors, where current treatment options may be limited, aiming to provide new avenues of therapy where they are most needed.
When was Salarius Pharmaceuticals founded?
Salarius Pharmaceuticals was founded in 2016. Since its inception, the company has been dedicated to advancing its innovative pipeline of therapeutic candidates, focusing on developing treatments that improve outcomes and quality of life for patients facing cancer.
Where is Salarius Pharmaceuticals located?
Salarius Pharmaceuticals is headquartered in Houston, Texas. The company's location in a major biotechnology and medical research hub allows it to collaborate with leading research institutions and access a network of talent and resources to advance its drug development programs.
Who are the key executives at Salarius Pharmaceuticals?
The leadership team at Salarius Pharmaceuticals includes experienced professionals with extensive backgrounds in biopharmaceuticals, research, and clinical development. Key executives typically include the CEO, COO, CFO, and heads of research and development, who collectively guide the company's strategic direction and growth.
What is the current price of Salarius Pharmaceuticals, Inc. - Common Stock?
The current price of Salarius Pharmaceuticals, Inc. - Common Stock is 0.7265
When was Salarius Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Salarius Pharmaceuticals, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Salarius Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Salarius Pharmaceuticals, Inc. - Common Stock is 32.53M
How many shares of Salarius Pharmaceuticals, Inc. - Common Stock are outstanding?
Salarius Pharmaceuticals, Inc. - Common Stock has 44.78M shares outstanding.